- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly raises forecast after beating third-quarter profit estimates
October 21, 2010
J.K. WallThe Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with
last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
MoreLilly suspends clinical trials after diabetes treatment fails
October 20, 2010
Bloomberg NewsEli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage
study, the second setback for a Lilly diabetes drug candidate in two days.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
MoreSome Lilly-paid docs sport spotty records
October 20, 2010
J.K. WallEli Lilly and Co. paid more than $102 million last year and early this year to physicians for talking up Lilly drugs to other
doctors. Yet 88 of the doctors Lilly pays have been sanctioned by state medical boards.
MoreFDA demands more tests on new Lilly diabetes drug
October 19, 2010
J.K. WallEli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly
version of diabetes drug Byetta, a potential billion-dollar drug.
MoreLilly to close drug discovery center in Singapore
October 18, 2010
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150
million plan to expand it.
MoreLilly falls short on 'field goal' attempt
October 13, 2010
J.K. WallEli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing
drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
MoreLilly's Erbitux shows mixed results in cancer studies
October 11, 2010
Bloomberg NewsIn combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread
of breast cancer in some patients with a certain type of aggressive tumor.
MoreCoordinating Lilly 'Day of Service' a major undertaking
October 7, 2010
Scott OlsonGetting 8,500 volunteers to where they're supposed to be along Interstate 70 relies on a system of color-coded passes.
By 6 p.m. Thursday, they'll have planted 1,600 trees and 72,000 shrubs and perennials (with photo gallery).
MoreConsultants: Pharma industry facing huge changes
October 6, 2010
J.K. Wall
To date, most analysts say health reform turned out pretty well for
the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver
a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen
over the past three decades.
Drugmakers’ ‘doughnut hole’ deal to shave sales
October 1, 2010
Bloomberg NewsDrugmakers including Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Co. and Eli Lilly and Co. may provide more than $2 billion
in drug discounts to senior citizens next year under a deal pharmaceutical companies made with the White House.
MoreLilly sues drug distributor over generic Zyprexa sales
September 29, 2010
Bloomberg NewsCelesio's Lloyds Pharmacy and Aah Pharmaceuticals businesses sold about 800,000 tablets of generic Zyprexa before agreeing
in 2008 to halt sales, Lilly said in a complaint filed in the High Court in London.
More$150M 'North of South' project moving ahead
September 27, 2010
IBJ StaffOfficials are announcing details of an ambitious downtown development planned for 10 acres Eli Lilly and Co. owns near its
Indianapolis headquarters. The project will include a hotel, apartments, restaurants and retail space and a YMCA.
MoreLilly discovers social media
September 22, 2010
J.K. WallEli Lilly and Co. launched its own blog this month, dubbed LillyPad, to try to start discussions about public policy and corporate
social responsibility. The Indianapolis-based drugmaker also launched an accompanying Twitter feed.
MoreLilly wins reversal of class action in Zyprexa suit
September 10, 2010
Bloomberg NewsA U.S. appeals court in New York threw out a September 2008 ruling that said plaintiffs could pursue as a group claims that
Zyprexa marketing caused them to pay more for the drug than what it was worth. The plaintiffs were seeking $6.8 billion in
damages.
MoreLilly investing up to $150M in VC funds
September 8, 2010
Bloomberg NewsThe three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each,
and Lilly will contribute as much as 20 percent of the money.
MoreLab used by Lilly, peers accused of animal cruelty
September 8, 2010
IBJ Staff and Associated PressAn investigation found that lab employees kicked, threw, and dragged dogs; lifted rabbits by their ears and puppies by their
throats; violently slammed cats into cages; and exposed animals to toxic chemicals.
MoreCEO says Lilly still not interested in huge acquisitions
September 7, 2010
IBJ Staff and Bloomberg NewsLilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter
said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
MoreAppeals court ruling upholds Lilly's Evista patents
September 1, 2010
Bloomberg NewsEli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic
version of the Evista osteoporosis treatment before March 2014.
MoreAfter health reform, Lilly looking for more
September 1, 2010
J.K. WallThe health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives
of the
bill—and calling for further government efforts to help pharmaceutical research and development.
MoreLilly wins ban of generic Strattera pending appeal
August 31, 2010
Bloomberg NewsThe U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until
the court rules on a judge's decision invalidating a patent on the medicine.
MoreA half-century later, Indiana Landmarks returns to roots
August 28, 2010
Cory Schouten
Bankrolled by yet another multimillionaire, the historic preservation group is preparing to move into a new headquarters
in Old Centrum, a former church now undergoing a big renovation.
Lilly wins further delay in sales of Strattera copies
August 26, 2010
Bloomberg NewsStrattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
MoreDiabetes research pioneer Kirtley dies at 96
August 25, 2010
Associated PressDiabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
MoreLilly woes take notch out of debt rating
August 25, 2010
J.K. WallEven with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
First, the Athenaeum is going to have to get past the hurdle with the Lockerbie residents and the agreement that the parcel would be residential. Second, and in my opinion, this prime piece of property should include parking, PLUS, a black box theater(s), some market rate and affordable artist housing and a plan to renovate and reconfigure the second story theater. I would negotiate to add the DeHaan property surface parking lot into the development mix, place a one story surface parking garage on the DeHaan lot on the street level (for the Dehaan tenants use during the daytime) and add a second story to the garage that would become an addition to the current second story theater and then change the direction of the theater by moving the stage across the alley and on top of the DeHaan lot parking. You can add all the stage elements that are currently missing from the Athenaeum stage to make it more attractive for use by Ballet, Opera and traveling productions. Plus, the theater changes would probably help solve some of the soundproofing issues. Alas,it does not seem to be a part of the strategic plan to conduct a study to determine best use of the property. Seems like the current plan is a quick and easy move that ignores the property best use/potential and any strategic property planning for the effect on future generations.
I recall that MSA's pilings are still in the ground and hard to remove. It’s not likely any proposal will include significant underground construction/parking because of this. Start adding 2 floors of retail, 8 floors of parking and 5-10 floors of possible hotel, and/or 10-20 floors of residential, and you are at 30 floors already with possible expansion of all the uses. But then again I could be wrong.
Accoriding to their website there is no deadline to the Do Not Call list. What is this article referring to??
On what planet are they entitled to this largesse from the stockholders? These people make multi-million dollar salaries: Pay for your own personal travel.
It matters because they're already paid enormously fat salaries: Pay for your own personal travel. Being "taxed on it" isn't a valid excuse--so what? They're still being gifted a raft of luxury perks from somebody else's money on top of an enormous, lavish salary.